Covidien plc Completes Enrollment in the DEFINITIVE AR Study
Published: Jan 15, 2013
MANSFIELD, Mass.--(BUSINESS WIRE)--Covidien (NYSE:COV), a leading global provider of healthcare products, today announced the completion of enrollment in its DEFINITIVE AR (Anti-Restenosis) study. As the third study in the DEFINITIVE trial series, this randomized pilot is designed to address the challenge of preventing restenosis (re-narrowing of a blood vessel following treatment), a common occurrence in patients with peripheral artery disease (PAD). According to the American Heart Association, approximately eight million people in the U.S. suffer from PAD.1 PAD affects blood vessels throughout the body. When the vessels become clogged with plaque, blood flow slows or stops. If left untreated in the legs or feet, for example, this condition can lead to severe pain when walking, gangrene and even amputation.